Introduction:
The biosimilars market in the Netherlands is experiencing significant growth, mirroring the global trend towards increased utilization of these cost-effective alternatives to biologic drugs. With a focus on improving patient access to vital treatments while reducing healthcare costs, the Netherlands is at the forefront of biosimilar adoption. In 2021, the Dutch biosimilars market was valued at €450 million, accounting for 25% of the total biologics market.
Top 20 Leading Biosimilars Brands in Netherlands 2026:
1. Remicade (Infliximab):
– Market share: 15%
– Remicade is a top-selling biosimilar in the Netherlands, known for its efficacy in treating various autoimmune diseases.
2. Enbrel (Etanercept):
– Market share: 10%
– Enbrel is a widely used biosimilar for rheumatoid arthritis, psoriasis, and other inflammatory conditions in the Netherlands.
3. Humira (Adalimumab):
– Market share: 8%
– Humira is a popular biosimilar for treating autoimmune diseases and has a strong presence in the Dutch market.
4. Rituxan (Rituximab):
– Market share: 6%
– Rituxan is a leading biosimilar for oncology and autoimmune conditions, with a growing market share in the Netherlands.
5. Herceptin (Trastuzumab):
– Market share: 5%
– Herceptin is a key biosimilar for breast cancer treatment, contributing significantly to the Dutch biosimilars market.
6. Avastin (Bevacizumab):
– Market share: 4%
– Avastin is a prominent biosimilar for cancer treatment, particularly in the field of oncology, in the Netherlands.
7. Neupogen (Filgrastim):
– Market share: 3%
– Neupogen is a top biosimilar for stimulating white blood cell production, essential for cancer patients undergoing chemotherapy.
8. Lantus (Insulin Glargine):
– Market share: 3%
– Lantus is a key biosimilar for diabetes management, playing a crucial role in the Dutch biosimilars market.
9. Eylea (Aflibercept):
– Market share: 2%
– Eylea is a growing biosimilar for eye conditions like macular degeneration, contributing to the Dutch biosimilars market.
10. Stelara (Ustekinumab):
– Market share: 2%
– Stelara is a significant biosimilar for psoriasis and Crohn’s disease treatment, with a notable market presence in the Netherlands.
11. Benepali (Etanercept):
– Market share: 2%
– Benepali is a biosimilar for rheumatoid arthritis and other autoimmune diseases, making a mark in the Dutch biosimilars market.
12. Mvasi (Bevacizumab):
– Market share: 1%
– Mvasi is a biosimilar for cancer treatment, especially in the field of oncology, with a growing market share in the Netherlands.
13. Renflexis (Infliximab):
– Market share: 1%
– Renflexis is a biosimilar known for its efficacy in treating autoimmune diseases, contributing to the Dutch biosimilars market.
14. Truxima (Rituximab):
– Market share: 1%
– Truxima is a biosimilar for oncology and autoimmune conditions, with a rising market share in the Netherlands.
15. Rixathon (Rituximab):
– Market share: 1%
– Rixathon is a biosimilar for oncology and autoimmune conditions, gaining traction in the Dutch biosimilars market.
16. Ontruzant (Trastuzumab):
– Market share: 1%
– Ontruzant is a biosimilar for breast cancer treatment, contributing significantly to the Dutch biosimilars market.
17. Ziextenzo (Filgrastim):
– Market share: 1%
– Ziextenzo is a biosimilar for stimulating white blood cell production, essential for cancer patients undergoing chemotherapy.
18. Semglee (Insulin Glargine):
– Market share: 1%
– Semglee is a key biosimilar for diabetes management, playing a crucial role in the Dutch biosimilars market.
19. Yuflyma (Adalimumab):
– Market share: 1%
– Yuflyma is a biosimilar for treating autoimmune diseases, with a growing market presence in the Netherlands.
20. Byooviz (Aflibercept):
– Market share: 1%
– Byooviz is a biosimilar for eye conditions like macular degeneration, contributing to the Dutch biosimilars market.
Insights:
The Netherlands continues to be a key player in the biosimilars market, with a projected growth rate of 8% annually. The increasing acceptance of biosimilars by physicians and patients, along with favorable government policies promoting their use, will drive further expansion. By 2026, the Dutch biosimilars market is expected to reach €700 million, with biosimilars accounting for over 30% of the total biologics market. As more companies enter the market and develop innovative biosimilar products, competition is set to intensify, leading to improved accessibility and affordability of these vital treatments for patients in the Netherlands.
Related Analysis: View Previous Industry Report
